Analysis of human reticulocyte genes reveals altered erythropoiesis: Potential use to detect recombinant human erythropoietin doping

Haematologica

Volumn 89, Issue 8, 2004, Pages 991-997

  Varlet Marie, Emmanuelle ^a   Audran, Michel ^a   Lejeune, Mireille ^b   Bonafoux, Béatrice ^b   Sicart, Marie Therese ^a   Marti, Jacques ^b   Piquemal, David ^a   Commes, Thérèse ^c  

^a UNIV MONTPELLIER   (France)

^b CNRS   (France)

^c INSTITUTE OF HUMAN GENETICS   (France)

Author keywords

Doping; Real time PCR analysis; Reticulocyte markers; RHuEpo; SAGE

Indexed keywords

ANTIZYME; EPREX 4000; FERRITIN; FERRITIN LIGHT CHAIN; HEMOGLOBIN BETA CHAIN; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHLETE; CONTROLLED STUDY; DOPING; DRUG ABUSE; DRUG MISUSE; ELECTROPHORESIS; ERYTHROPOIESIS; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MARKER GENE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OXYGEN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; RETICULOCYTE; SERIAL ANALYSIS OF GENE EXPRESSION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; DOPING IN SPORTS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; GENE EXPRESSION REGULATION; HUMANS; PLACEBOS; POLYMERASE CHAIN REACTION; RETICULOCYTES; RNA, MESSENGER; SPORTS;

EID: 3943075045     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jelkman W. Biology of erythropoietin. Clin Invest 1994;72:S3-S10.
2. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63.
3. Sawka MN, Joyner MJ, Miles DS, Robertson RJ, Spriet LL, Young AJ. American College of Sports Medicine position stand. The use of blood doping as an ergogenic aid. Med Sci Sports Exerc 1996;28:1-8.
4. Berglund B, Ekblom B. Effect of recombiant human erythropoietin treatment on blood pressure and some haematological parameters in healthy males. J Int Med 1991;229:125-30.
5. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports 1991;1:88-93.
6. Kicman AT, Cowan DA. Peptide hormones and sport: misuse and detection. Br Med Bull 1992;48:496-517.
7. Lasne F, De Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000;405:635.
8. Lasne F. Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 2001;253:125-31.
9. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 1999;31:639-45.
10. Birkeland K, Hemmersbach P. Issues related to blood sampling in athletes for doping control. Sports Med 1999;28:25-30.
11. Birkeland K, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 2000;32:1238-43.
12. Bressolle F, Audran M, Gareau R, Pham TN, Gomeni R. Population pharmacodynamics for monitoring epoetin in athletes. Clin Drug Invest 1997;14:233-42.
13. Casoni I, Ricci G, Ballarin E, Borsetto C, Grazzi G, Guglielmini C, et al. Haematological indices of erythropoietin administration in athletes. Int J Sports Med 1993;14:307-11.
14. Gareau R, Gagnon MG, Thellend C, Chenard C, Audran M, Chanal JL, et al. Transferrin soluble receptor: a possible probe for detection of erythropoietin abuse by athletes. Horm Metab Res 1994;26:311-2.
15. Gore C, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 2003;88:333-44.
16. Magnani M, Corsi D, Bianchi M, Paiardini M, Galluzzi L, Gargiullo E, et al. Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes. Blood Cells Mol Dis 2001;27:559-71.
17. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, et al. A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000;85:564-72.
18. Parisotto R, Gore CJ, Hahn AG, Ashenden MJ, Olds TS, Martin DT, et al. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J Sports Med 2000;21:471-9.
19. Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol 2002;86:442-9.
20. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996;42:355-60.
21. Cotes PM, Brozovic B. Diurnal variation of serum immunoreactive erythropoietin in a normal subject. Clin Endocrinol 1982;17:419-22.
22. Miller ME, Garcia JF, Cohen RA, Cronkite EP, Moccia G, Acevedo J, et al. Diurnal levels of immunoreactive erythropoietin in normal subjects and subjects with chronic lung disease. BrJ Haematol 1981;49:189-200.
23. Piquemal D, Commes T, Manchon L, Lejeune M, Ferraz C, Pugnere D, et al. Transcriptome analysis of monocytic leukemia cell differentiation. Genomics 2002;80:361-71.
24. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2000;85:561-3.